Načítá se...
Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis
BACKGROUND: To estimate the cost -utility of imrecoxib compared with diclofenac, as well as the addition of a proton pump inhibitor to both two treatment strategies, for patients with osteoarthritis, from a Chinese healthcare perspective. METHODS: A Markov model was built. Costs of managing osteoart...
Uloženo v:
| Vydáno v: | Cost Eff Resour Alloc |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8056517/ https://ncbi.nlm.nih.gov/pubmed/33879168 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-021-00275-7 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|